Payment overview · 2025
General Payments
$824.15
19 reported records · 9 companies
Healthcare provider profile · identity verified
Sandhya-Rani Mokkala, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WEBSTER, TX · NPI 1447261839
Verified facts
What the public records show
CMS Open Payments records show Sandhya-Rani Mokkala, M.D. received $824.15 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $178.77 | 21.7% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $169.75 | 20.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $158.79 | 19.3% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $124.08 | 15.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$86.42 | 10.5% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $50.68 | 6.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.01 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.16 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.49 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $791.88 | 18 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $169.75 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $124.08 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $86.42 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $71.94 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $70.70 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $50.68 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.99 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 157 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 541 | 164 |
| Losartan Potassium | Losartan Potassium | 336 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 90 |
| Lisinopril | Lisinopril | 239 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 236 | 75 |
| Metformin Hcl | Metformin Hcl | 230 | 71 |
| Gabapentin | Gabapentin | 224 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 67 |
| Furosemide | Furosemide | 189 | 68 |
| Montelukast Sodium | Montelukast Sodium | 165 | 43 |
| Azithromycin | Azithromycin | 160 | 123 |
| Jardiance | Empagliflozin | 157 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 153 | 48 |
| Carvedilol | Carvedilol | 152 | 45 |
| Simvastatin | Simvastatin | 151 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 41 |
| Omeprazole | Omeprazole | 145 | 43 |
| Ozempic | Semaglutide | 134 | 29 |
| Tramadol Hcl | Tramadol Hcl | 118 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 46 |
| Glipizide | Glipizide | 113 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 42 |
| Alendronate Sodium | Alendronate Sodium | 110 | 32 |
| Sertraline Hcl | Sertraline Hcl | 109 | 28 |
| Cephalexin | Cephalexin | 106 | 83 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 106 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 35 |
| Eliquis | Apixaban | 94 | 25 |
| Trazodone Hcl | Trazodone Hcl | 86 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 26 |
| Meloxicam | Meloxicam | 77 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 20 |
| Ezetimibe | Ezetimibe | 70 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 69 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 20 |
| Allopurinol | Allopurinol | 68 | 24 |
| Prednisone | Prednisone | 63 | 55 |
| Potassium Chloride | Potassium Chloride | 62 | 20 |
| Synthroid | Levothyroxine Sodium | 61 | 18 |
| Gemfibrozil | Gemfibrozil | 60 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 22 |
| Alprazolam | Alprazolam | 54 | 17 |
| Atenolol | Atenolol | 49 | 15 |
| Clonazepam | Clonazepam | 49 | 11 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 39 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Valsartan | Valsartan | 43 | 13 |
| Buspirone Hcl | Buspirone Hcl | 42 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 12 |
| Primidone | Primidone | 42 | 13 |
| Eszopiclone | Eszopiclone | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 41 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 26 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | 14 |
| Finasteride | Finasteride | 33 | 13 |
| Methocarbamol | Methocarbamol | 33 | 18 |
| Bupropion Hcl | Bupropion Hcl | 32 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 32 | suppressed |
| Topiramate | Topiramate | 32 | 11 |
| Cefuroxime | Cefuroxime Axetil | 31 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 17 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 11 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 26 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | 12 |
| Fluconazole | Fluconazole | 24 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Ramipril | Ramipril | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 16 |
| Repaglinide | Repaglinide | 19 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Zolmitriptan | Zolmitriptan | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $824.15 · 19 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, CARDIOMEMS, FARXIGA, INSPIRE, JARDIANCE, MOUNJARO, Ozempic, Rybelsus, SHINGRIX, Senza, VENASEAL, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error